Navigation Links
MacroGenics Initiates Phase I Clinical Trial of MGAH22 for Patients With HER2-Expressing Solid Tumors
Date:1/6/2011

ut MacroGenics, Inc.

MacroGenics is a private, venture-backed biotechnology company that focuses on the discovery, development and delivery to patients of novel biologics for autoimmune disorders, cancer and infectious diseases. The company has built a fully-integrated set of capabilities in antibody-based product development which supports its innovative pipeline of clinical stage product candidates. MacroGenics' proprietary research is based on three core technology platforms, which include: (1) a method for generating cancer stem-like cells; (2) Dual-Affinity Re-Targeting (or DART™) technology, which allows the company to incorporate multiple specificities within a single recombinant molecule; and (3) Fc optimization, which enhances antibody-dependent effector functions. The company has global product development collaborations with Boehringer Ingelheim, Pfizer Inc. and Eli Lilly and Company.  For more information about MacroGenics, please visit www.macrogenics.com.

Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, and risks related to the Company's ability to initiate, and enroll patients in, planned clinical trials. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by law.  

'/>"/>

SOURCE MacroGenics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. MacroGenics Enters Global Research Collaboration and License Agreement with Pfizer
2. MacroGenics Receives NIH Grant Funding of $9.8M for Three Projects; Funding Further Advances DART Platform and Infectious Disease Portfolio
3. MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus
4. Paulo F. Costa Joins MacroGenics Board of Directors
5. MacroGenics Appoints New Vice President of Business Development
6. MacroGenics Raises $25M in Series D-2 Financing
7. Vaccinex, Inc. Initiates Clinical Trial of Novel Therapeutic Antibody in Cancer Patients With Advanced Solid Tumors
8. Tolerx Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer
9. Pfizer Stops Clinical Trials of Thelin® and Initiates Voluntary Product Withdrawal in the Interest of Patient Safety
10. GeNO LLC Initiates Phase 2 Trial For Nitric Oxide Delivery System
11. SPECTRAL INITIATES U.S. PIVOTAL TRIAL OF TORAYMYXIN™ IN SEPTIC SHOCK
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Sept. 17, 2014  The In Silico Drug Discovery ... be featured at the conference, which takes place at ... 3 and 4, 2014. Researchers, students, drug developers, business ... the following: KEYNOTE SPEAKERS ... Skaggs School of Pharmacy Drug Discovery with ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 A ... occurring microorganisms such as bacteria, fungi, and algae ... water, methane, biomass, inorganic compounds, carbon dioxide, and ... expanding customer base and improved costs, biodegradable polymers ... economically viable alternative to conventional polymers. Primary factors ...
(Date:9/17/2014)... Terracon Corporation has announced the introduction of ... This addition to the company’s industry-leading line of ... and available in 125 or 250 gallon capacities. ... weeks or less. , The new pre-engineered TerraPure tank ... existing TerraPure tank line – plus quick turnaround. ...
(Date:9/17/2014)... 2014 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD) (OTCQX: ... proprietary technologies and products for advanced microarray diagnostics, today ... trading in the United States ... commence on September 17, 2014 on the OTCQX under ... on the TSX Venture Exchange under its existing symbol ...
Breaking Biology Technology:In Silico Drug Discovery Conference Announces Speakers and Topics 2In Silico Drug Discovery Conference Announces Speakers and Topics 3In Silico Drug Discovery Conference Announces Speakers and Topics 4In Silico Drug Discovery Conference Announces Speakers and Topics 5In Silico Drug Discovery Conference Announces Speakers and Topics 6In Silico Drug Discovery Conference Announces Speakers and Topics 7Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 3Terracon Introduces Pre-Engineered TerraPure® Tank for Ultrapure Water Applications 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 3
... Biotech and pharma,companies are increasingly relying on ... Engineering & Biotechnology News (GEN). The,technique can provide ... drug,candidates for toxic effects, according to an article ... )., "Better screening technologies, noninvasive monitoring, and ...
... /PRNewswire-FirstCall/ - Oncothyreon Inc.,(Nasdaq: ONTY ) (TSX:ONY) ... and preclinical studies of PX-866 were presented at ... Research (AACR) in,San Diego, held April 12-16, 2008. ... plans for these product candidates. Oncothyreon,is currently conducting ...
... Anavex Life,Sciences Corp. ("ANAVEX") (OTCBB: AVXL) today announced ... of Clinical Development as the,company prepares to enter ... the next 12 months., Dr. Goundis has ... of,clinical trials, including leadership positions at Speedel AG ...
Cached Biology Technology:Genetic Engineering & Biotechnology News Reports on Growing Use of Cell-Based Assays 2Data for Oncothyreon's PX-12 and PX-866 presented at AACR Annual Meeting 2Data for Oncothyreon's PX-12 and PX-866 presented at AACR Annual Meeting 3Data for Oncothyreon's PX-12 and PX-866 presented at AACR Annual Meeting 4Data for Oncothyreon's PX-12 and PX-866 presented at AACR Annual Meeting 5Anavex appoints Dr. Dimitri Goundis to lead Clinical Development 2Anavex appoints Dr. Dimitri Goundis to lead Clinical Development 3Anavex appoints Dr. Dimitri Goundis to lead Clinical Development 4
(Date:9/16/2014)... at the Columbia Center for Children,s Environmental Health at ... to demonstrate an association between childhood asthma and prenatal ... of household products. Results appear online in the journal ... to mothers exposed during pregnancy to higher levels of ... had a 72 percent and 78 percent increase in ...
(Date:9/16/2014)... Hopkins neuroscientists have discovered the "molecular brakes" that time ... cochleas of mice. These "hair cells" translate sound waves ... and are interpreted as sounds. If the arrangement of ... A summary of the research will be published in ... , "The proteins Hey1 and Hey2 act as brakes ...
(Date:9/16/2014)... EUGENE, Ore. -- Each tree species has its own ... researchers and colleagues from other institutions who studied the ... growing on a Panamanian island. , "This study demonstrates ... plant families and with different ecological strategies possess very ... Steven W. Kembel, a former postdoctoral researcher in the ...
Breaking Biology News(10 mins):Phthalates heighten risk for childhood asthma 2Phthalates heighten risk for childhood asthma 3Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2Microbiome research shows each tree species has a unique bacterial identity 2
... be difficult for a terrorist to obtain genes from the ... Armed with a fake email address, a would-be bioterrorist could ... online, and receive them by post within weeks. , That's ... the bioterror risks posed by the booming business of gene ...
... students have discovered the antler of an Irish Elk in cliffs ... the exact age of the antler has yet to be determined, ... lived around 11,000 years ago. The giant deer roamed the open ... of the last Ice Age, as the glaciers retreated northwards. ...
... Medical Institute researchers have discovered that pheromones essential for ... and not by the vomeronasal system, as researchers had ... epithelium, which was presumed to be mostly involved with ... pheromone detection. , Howard Hughes Medical Institute investigator ...
Cached Biology News:The bioweapon is in the post 2The bioweapon is in the post 3The bioweapon is in the post 4Students discover 11,000 year old remains of Irish Elk 2Olfactory system detects pheromones that control reproduction 2Olfactory system detects pheromones that control reproduction 3Olfactory system detects pheromones that control reproduction 4
... patented technology, the Lone Wolf valve has ... Open proportional valve available on the market. ... repeatable high-speed performance, and ensures maximum accuracy., ... Enhances system control and patient comfort. , ...
... offers the same benefits as the VSO valve ... is critical or flow is required below 600 ... of gas in proportion to the input current., ... width modulation; closed loop feedback delivers optimal system ...
... from non-demolished blood that is ... The donors are not medicated ... maintained on an antibiotic free ... : 85 mg/ml (by Refractometry).Strain: ...
... 96-well Filter Plates are offered in several ... um depth filter plates are ideal to ... Filtration is simple, versatile, and necessary to ... Captiva 10 um glass fiber and 20 ...
Biology Products: